A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)

A Phase Ib/II Multicenter, Randomized, Open-label, Active-controlled, Single/Multiple-dose, Dose-finding, Clinical Study of GenSci134 in Children With Growth Hormone Deficiency

This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation to assess safety, tolerability, PK/PD profile, and immunogenicity of GenSci134 in children with GHD.

Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with GHD. It will also evaluate PK/PD profile and immunogenicity to support dose selection for Phase III.

Study Overview

• Status: Not yet recruiting
• Conditions: Pediatric Growth Hormone Deficiency
• Intervention / Treatment: Drug: GenSci134 Injection; Drug: Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)

• Study Type: Interventional
• Enrollment (Estimated): 128
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Jinbo Li; Phone Number: +86 15001322766; Email: lijinbo@genscigroup.com

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430000
      • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Informed consent of parent or legal representative of participant and child assent, as age appropriate must be obtained before any study-related activities.

2. At the time of signing the Informed consent form (ICF), the following conditions must be met:

   Phase Ib:

   Girls: age ≥3and ≤11 years, breast development at Tanner stage 1, body weight ≥16 kg; Boys: age ≥3 and ≤12 years, testis volume <4 mL, body weight ≥16 kg.

   Phase II:

   Girls: age ≥3 and ≤9 years, breast development at Tanner stage 1; Boys: age ≥3 and ≤10 years, testis volume <4 mL.

3. BMI within the range of ±2 SD of the mean BMI for age and sex at screening
4. Height is at least 2 SD below the mean HT for age and sex (HT SDS ≤ -2.0) at screening according to the normal pediatric population standards
5. Diagnosis of GHD confirmed by two different GH stimulation tests performed at screening or within 12 months prior to screening.
6. No prior exposure to GH or IGF-1therapy.
7. Absence of intracranial tumor, as confirmed by MRI or CT. Images or scans obtained within 1 year prior to screening can be used as screening data if accompanied by a medical evaluation and conclusion.
8. AHV <5 cm/year at screening (Phase II only);
9. BA < CA at screening (Phase II only);
10. IGF-1 SDS ≤ -1.0 at screening (Phase II only).

Exclusion Criteria:

1. Presence of one or more pituitary hormone deficiencies in addition to growth hormone deficiency.

2. Any suspected or known disease likely to affect growth, or any clinically significant abnormality that would preclude the accurate assessment of standing height (Phase II only), including but not limited to:

   • Turner syndrome
   • Noonan syndrome
   • Laron Syndrome
   • Other genetic syndromes with short stature that are caused by chromosomal abnormalities or gene mutations, including but not limited to Prader-Willi syndrome, abnormal SHOX-1 gene analysis, or GH receptor deficiency.
   • Born small for gestational age
   • Growth retardation due to malnutrition
   • Growth retardation due to hypothyroidism.
   • Short stature with any other clearly identified etiology.
   • Congenital abnormalities causing skeletal abnormalities, or claudication (Phase II only).
   • Significant spinal abnormalities (Phase II only).
3. Epiphyseal closure (Phase II only).
4. Abnormal liver function, renal function, or coagulation profile
5. Current or prior history of any malignant disease; or a family history of malignancy.
6. Presence of impaired glucose metabolism, or HbA1c ≥ 5.7%, or a confirmed diagnosis of diabetes mellitus.
7. Clear medical history of cardiovascular, hepatic, renal, gastrointestinal, respiratory, hematological, neurological, or metabolic disorders, or any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in the study.
8. Any clinically significant abnormality in vital signs, physical examinations, laboratory tests, 12-lead ECG, full spine anteroposterior and lateral X-ray, or B-mode ultrasound, other than those associated with the study disease, as judged by the investigator and will make the participant unsuitable for the study.
9. A positive result for any of the following serological tests during the screening period: HBsAg, Anti-HCV, Anti-HIV, or TP-Ab.
10. Known highly allergic diathesis or hypersensitivity to growth hormone products or any excipient of the investigational drug.
11. Participation in another clinical trial within 3 months prior to screening, or if the time since the last dose is less than 5 half-lives of the previous investigational drug at screening.
12. Receipt of any blood products within 3 months prior to the first dose, poor peripheral venous access, or any medical condition that will preclude tolerance of the blood sampling procedures.
13. Administration of any vaccine within 14 days prior to the first dose or planned vaccination at any time during the study period.
14. The participant and/or the parent/legal representative is likely to be non-compliant with respect to study conduct, as judged by the investigator.
15. Children have been treated with systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening (Phase II only).
16. Children have been treated with inhaled glucocorticoid therapy at a dose greater than 400 µg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening (Phase II only).
17. Receipt within 3 months prior to screening or planned use during the study of medications that may interfere with growth or development (Phase II only).
18. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose Level 1~ Dose Level 6; dose level 1、dose level 2、dose level 3、dose level 4、 dose level 5、dose level 6	Drug: GenSci134 Injection; only one dose of GenSci134 to be given, subcutaneous , 6 dose levels will be assigned.; Other Names: GenSci134
Active Comparator: Recombinant Human Growth Hormone Injection (Norditropin®); Active control group	Drug: Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®); multiple doses of Norditropin® FlexPro® quaque die (QD) for 28 consecutive days by subcutaneous injections.; Other Names: Norditropin®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Phase II: Annualized height velocity (AHV) at Week 24 of treatment	24 weeks
Phase Ib: Treatment Emergent Adverse Events （TEAEs）	From the first dose to Day 35

Secondary Outcome Measures

Outcome Measure	Time Frame
Phase Ib: Areas under the drug concentration-time curve (AUC0-t, AUC0-∞) of GenSci134	From Day 1 to Day 29
Phase Ib: Time to maximum concentration (Tmax) of GenSci134	From Day 1 to Day 29
Phase Ib: Maximum concentration (Cmax) of GenSci134	From Day 1 to Day 29
Phase Ib: Half-life (t1/2) of GenSci134	From Day 1 to Day 29
Phase Ib: Incidence and timing of positive anti-drug antibody (ADA) and/or neutralizing antibody (NAb) (if applicable)	From Day 1 to Day 29
Phase Ib: Serum level of IGF-1 and IGFBP-3 and their changes from baseline.	From Day 1 to Day 29
Phase II: Change from baseline in HT SDS at each visit	From baseline to Week 28 of the extension period
Phase II: Change from baseline in AHV at each visit	From baseline to Week 28 of the extension period
Phase II: Change from baseline in BA/CA at each visit.	From baseline to Week 28 of the extension period
Phase II: Treatment Emergent Adverse Events（TEAEs）	From the first dose to Week 29 of the extension period
Phase II: Serum concentration of GenSci134.	From baseline to Week 28 of the extension period
Phase II: Serum level of IGF-1and IGFBP-3 and their changes from baseline.	From baseline to Week 28 of the extension period
Phase II: Incidence and timing of positive ADA and/or NAb (if applicable).	From baseline to Week 28 of the extension period

Collaborators and Investigators

• Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): March 6, 2026
• Primary Completion (Estimated): July 18, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: February 12, 2026
• First Submitted That Met QC Criteria: February 27, 2026
• First Posted (Actual): March 4, 2026

Study Record Updates

• Last Update Posted (Actual): March 4, 2026
• Last Update Submitted That Met QC Criteria: February 27, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: PGHD; GenSci134
• Additional Relevant MeSH Terms: Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptide Hormones; Peptides; Amino Acids, Peptides, and Proteins; Pituitary Hormones; Growth Hormone; Pituitary Hormones, Anterior; Human Growth Hormone
• Other Study ID Numbers: GenSci134-202

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No